Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and potential new partnerships this year as the company continues developing MultiStem and its 5HT2C agonist program. Athersys CEO Gil Van […]
A University of Texas spinoff company has pulled in $2 million to test a new technique for culturing non-embryonic stem cells. According to a regulatory filing, StemBioSys raised at least $2 million of a $3.5 million equity offering. A company representative was not available to elaborate, but CEO Dr. Steven Davis told the San Antonio […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If you are having a hard time choosing between President Barack Obama and Republican nominee Gov. Mitt Romney, here are some weekend reading assignments for you. Whether you’re interested in stem cell research or Jeep jobs or Medicare, these independent websites (no lamestream media here) let you check the truthiness of candidate claims and understand […]
It’s easy to look at Nobel Prize winners and assume the greatness of their work. But it’s even more awe-inspiring to understand the research and see it in action. This year, the Nobel Prize in physiology or medicine was given to regenerative medicine researchers Sir. John B. Gurdon of the University of Cambridge and Shinya […]
A California regenerative medicine firm raised $9.2 million and is planning new clinical trials for its stem cell modulator in patients with blood cancer. Read more.
A cure for spinal cord injury? Diabetes? Macular degeneration? Hope or just hype? There are now some clinical trials using embryonic stem cells to treat serious diseases for which no other good therapy is currently available. But this is just the beginning of a major medical megatrend that will blossom forth in the coming years. […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
UPDATED Under the umbrella of regenerative medicine, cell therapies are the foundation of many of the companies developing the next wave of drugs for diseases of the nervous system, cancer, cardiac disorders, diabetes and genetic disorders, just to name a few. To help researchers and, eventually, clinicians, using cell therapies, West Coast startup Bell Biosystems […]
Imagine a man with a recent severe heart attack who has the muscle repaired with stem cells or a child with a severe bladder defect repaired with stem cells grown on a biodegradable scaffold. Sounds like science fiction but these are actual clinical studies in progress today. Stem cell therapies promise to be one of […]
New cells to replace those destroyed in diabetes type 1, cells to help heal a heart attack, cells to cure leukemia — this is the promise of stem cells. Some of this is happening now; more will be available in a few years.” Stem cells will usher in the era of regenerative medicine, allowing the […]
A company’s new technique to improve female infertility treatment based on the controversial idea that women aren’t in fact born with a finite number of eggs is getting the attention of investors — to the tune of more than $38 million raised this year. It looks like OvaScience Inc., a startup working on improving female […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The regenerative medicine company Juventas Therapeutics, which had already said it added Takeda Pharmaceuticals to its roster of investors, said this weekend it has raised enough money to take its treatments for heart failure and a severe form of peripheral artery disease through its latest round of clinical trials. The $22.2 million investment will be […]
Regenerative medicine wound healing company SironRX Therapeutics has hired a first-time CEO as its first-ever, full-time CEO. Evan Facher most recently worked as general manager of Pittsburgh interventional operations with MedRad, a medical device company that’s an arm of Bayer HealthCare. In eight years with MedRad, Facher held a variety of roles that included business […]
It isn’t easy to get profit-hungry Wall Street excited about a drug that hasn’t yet been tested in humans and is at best years and years away from generating any sales, but Athersys (NASDAQ:ATHX) CEO Gil Van Bokkelen did his best in a recent conference call with investment analysts. That’s because there are recent signs […]
When regenerative medicine firm Cytomedix (OTC:CMXI) acquired biotechnology company Aldagen, the stem cell-based stroke treatment in clinical trials was the centerpiece of the all stock deal. Cytomedix is now making moves to develop other stem cell treatments from its Aldagen acquisition. Two more clinical trials will start later this year, CEO Martin Rosendale told analysts […]
Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients. The Cleveland-based company, which recently secured an important investment from Takeda Pharmaceuticals, is planning to enroll 48 patients and complete enrollment early next year, CEO Rahul Aras said. Juventas’ technology, called JVS-100, works by recruiting stem cells […]